ArticleEuropean journal of nuclear medicine and molecular imaging2018
ImmunoPET imaging of CD38 in murine lymphoma models using
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical PET Imaging Evaluation of 68Ga-NB381 Probe in Multiple Myeloma
Clinical PET Imaging Evaluation of 68Ga-BC1 Probe in Multiple Myeloma
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy.Nuclear medicine and molecular imaging · 2026Review
- PET Imaging of CD38 and IND enabling studies of [Molecular imaging and biology · 2026Article
- Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.European journal of nuclear medicine and molecular imaging · 2025Article
- [American journal of nuclear medicine and molecular imaging · 2025Article
- CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity.Molecular therapy. Oncology · 2024Article
- Development of New CD38 Targeted Peptides for Cancer Imaging.Molecular imaging and biology · 2024Article
- Theranostic role ofEuropean journal of nuclear medicine and molecular imaging · 2024Article
- CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20.Clinical and translational science · 2024Article
- Dive into the details of radionuclide antibody conjugates: what role do EPR effects and LETs of different radionuclides play?American journal of nuclear medicine and molecular imaging · 2023Article
- Article
- CD38-specific nanobodies allowFrontiers in immunology · 2022Article
- Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine.Journal of nanobiotechnology · 2021Article
- ImmunoPET imaging of multiple myeloma with [European journal of nuclear medicine and molecular imaging · 2021Article
- ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models.Bioconjugate chemistry · 2021Article
- CD38-Targeted Theranostics of Lymphoma withAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Development of [European journal of nuclear medicine and molecular imaging · 2021Article
- Noninvasive Evaluation of CD20 Expression UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeCD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with
methodsDaratumumab was radiolabeled with
resultsUsing WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and
conclusionsThe role of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.